BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
BOTHELL, Wash., Jan. 18, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS) announced today that it has significantly increased its financial support for several key organizations in the regenerative medicine industry. The worldwide regenerative medicine market is comprised of nearly 1,000 commercial companies and hospitals, which are developing cell and tissue-based products and therapies to treat cancer, heart disease, diabetes, neurologic disorders, movement disorders, and many other afflictions.
Chairman and CEO Mike Rice explained the Company's interest to support the regenerative medicine industry by stating, "The regenerative medicine industry is a strategic market segment for BioLife, where the critical value of our novel, clinical grade biopreservation media products continues to be recognized by a growing number of commercial companies and hospital-based transfusion centers. We understand that broad-based, worldwide adoption of any novel, enabling technologies such as our HypoThermosol® and CryoStor® products must be driven by scientific proof and a thorough vetting of the supplier's operations and quality systems, and we're actively engaged in these organizations by holding committee membership positions, presenting at scientific conferences, and contributing to the creation of best practices documents and standards that can improve the quality of the manufacturing, transportation, infusion, and clinical efficacy of new cell and tissue-based regenerative medicine products and therapies."
Most recently, BioLife joined the Alliance for Regenerative Medicine (ARM) as a corporate member for 2011. ARM is a Washington, DC-based non-profit organization whose mission is to ed